Expert Interview
Reviewing commercial options for PAH, including Tyvaso, Yutrepia and Winrevair
Ticker(s): LQDA, UTHR, MRKInstitution: Holy Cross Health
- Pulmonogist - Medical Director affiliated with Holy Cross Health
- Sees 121 PAH patients, has 14 on Yutrepia
- Over 25 years experience in the medical field
In which patients are you using Yutrepia on?
Added By: wilson_adminComparing the 3 options, do you have a preference?
Added By: wilson_adminAny options on investigational therapies in PAH?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
